News - Allergan, Neurological


Current filters:


Popular Filters

Review of key drivers of migraine market growth through 2022


Use of Allergan’s Botox (botulinum toxin type A) for the prophylactic treatment of chronic migraine…

AllerganAsia-PacificBotoxCoLucid PharmaceuticalsEuropelasmiditanLevadexMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

FDA sends CRL rejecting Allergan's migraine drug Levadex on quality issues


US drugmaker Allergan (NYSE: AGN) said yesterday (April 16) that the US Food and Drug Administration…

AllerganLevadexNeurologicalNorth AmericaPharmaceuticalProductionRegulation

Allergan to acquire MAP Pharmaceuticals in $958 million deal


US drugmaker Allergan (NYSE: AGN) has entered into a definitive merger agreement to acquire 100% of the…

AllerganLevadexMAP PharmaceuticalsMergers & AcquisitionsNeurologicalPharmaceutical

FDA approves Allergan's Botox for OAB and NuPathe's Zecuity for migraine


US drugmaker Allergan (NYSE: AGN) says that the US Food and Drug Administration has approved its Botox…

AllerganBotoxGenito-urinaryNeurologicalNorth AmericaNuPathePharmaceuticalRegulationZecuity

Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox


UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published…

AllerganBotoxEuropeGlaxoSmithKlineHerceptinJanssenJohnson & JohnsonNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarcevaTyverbZytiga

UK's NICE negative on Sanofi's Jevtana, but backs Botox for migraine


Confirming previous negative guidance (The Pharma Letter January 12), UK drugs watchdog the National…


FDA delay for MAP Pharma migraine drug candidate


Shares of USA-based MAP Pharmaceuticals (Nasdaq: MAPP) plunged 24% to $13.01 in early trading yesterday,…

AllerganLevadexMAP PharmaceuticalsMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulation

UK NICE asks for more data on Tarceva, and Botox for migraine


UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) today issued new draft…


Allergan gets US FDA nod for Botox to treat form of urinary incontinence


There was a boost for US specialty drug firm Allergan (NYSE: AGN) yesterday when the company revealed…

AllerganBotoxNeurologicalNorth AmericaPharmaceuticalRegulation

MAP Pharma gets $20 million milestone as US FDA accepts Levadex NDA


California, USA-based MAP Pharmaceuticals (Nasdaq: MAPP) says that its New Drug Application for Levadex…

AllerganLevadexMAP PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulation

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top